采用高敏肌钙蛋白快速算法评估疑似急性心肌梗死患者的外部验证
本研究为多中心前瞻性观察研究,纳入2020年11月至2021年9月5家澳大利亚医院急诊成年的疑似AMI(无ST段抬高型MI)患者1994例,平均年龄56.2岁(SD=15.6),44.9%为女性。采用Siemens Atellica IM hs-cTnI实验室检测,测定入院时及2-3小时肌钙蛋白浓度,并由心脏科医生裁定最终诊断。评估HighSTEACS诊断算法(结合入院时hs-cTnI浓度及2-3小时内绝对变化),主要终点为指数AMI(包括1型或2型NSTEMI或就诊后STEMI),并报告30天主要不良心脏结局。结果显示118例(5.9%)确诊指数AMI;2小时算法将61.3%患者定义为低危,敏感性99.1%(94.0%-99.9%),阴性预测值99.9%(99.3%-100%);24.4%为中危;14.3%(252例)为高危,特异性91.5%(88.7%-93.6%),阳性预测值42.0%(35.6-48.7%)。作者认为该算法可对急诊疑似AMI患者进行安全高效的风险评估。
要点
- 2小时HighSTEACS算法基于Siemens Atellica IM hs-CtnI,将61.3%的急诊疑似AMI患者划为低危,敏感性99.1%(94.0%-99.9%),阴性预测值99.9%(99.3%-100%)。
- 该算法将24.4%患者划为中危,14.3%(252例)划为高危,高危组特异性91.5%(88.7%-93.6%),阳性预测值42.0%(35.6-48.7%)。
- 研究纳入1994例无ST段抬高型MI的急诊成人患者,118例(5.9%)确诊指数AMI。
- 作者结论认为,基于HighSTEACS策略的2小时算法使用Siemens Atellica IM hs-cTnI实验室检测,可对急诊疑似AMI患者进行安全高效的风险评估。
适用人群与场景
- 澳大利亚5家医院急诊科就诊的成年患者,有疑似急性心肌梗死症状,且就诊心电图无ST段抬高型心肌梗死。
诊断标准与关键阈值
- HighSTEACS诊断算法:结合入院时hs-cTnI浓度及2-3小时内绝对变化,将患者分为低危、中危和高危;2小时算法定义61.3%为低危,24.4%为中危,14.3%为高危。
研究设计与关键结果
- 多中心前瞻性观察研究,纳入5家澳大利亚医院1994例急诊疑似AMI患者,平均年龄56.2岁(SD=15.6),44.9%为女性,118例(5.9%)确诊指数AMI。
- 2小时算法将61.3%患者定义为低危,敏感性99.1%(94.0%-99.9%),阴性预测值99.9%(99.3%-100%)。
- 24.4%患者为中危;高危组252例(14.3%),特异性91.5%(88.7%-93.6%),阳性预测值42.0%(35.6-48.7%)。
- 30天主要不良心脏结局(包括AMI、紧急血运重建或心源性死亡)也有报告。
证据类型、等级与局限
- 证据类型:多中心前瞻性观察研究(外部验证)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,基于HighSTEACS策略的2小时算法使用Siemens Atellica IM hs-CtnI实验室检测,可对急诊疑似AMI患者进行安全高效的风险评估。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: We sought to validate the clinical performance of a rapid assessment pathway incorporating the Siemens Atellica IM high sensitivity cardiac troponin I (hs-cTnI) assay in patients presenting to the emergency department (ED) with suspected acute myocardial infarction (AMI).
METHODS: This was a multicentre prospective observational study of adult ED patients presenting to five Australian hospitals between November 2020 and September 2021. Participants included those with symptoms of suspected AMI (without ST-segment elevation MI on presentation ECG). The Siemen's Atellica IM hs-cTnI laboratory-based assay was used to measure troponin concentrations at admission and after 2-3 hours and cardiologists adjudicated final diagnoses. The HighSTEACS diagnostic algorithm was evaluated, incorporating hs-cTnI concentrations at presentation and absolute changes within the first 2 to 3 hours. The primary outcome was index AMI, including type 1 or 2 non-ST segment elevation MI (NSTEMI) or ST-elevation MI (STEMI) following presentation. 30-day major adverse cardiac outcomes (including AMI, urgent revascularisation or cardiac death) were also reported. The trial was registered with the Australian and New Zealand Clinical Trials Registry.
RESULTS: 1994 patients were included. The average age was 56.2 years (SD=15.6), and 44.9% were women. 118 (5.9%) patients had confirmed index AMI. The 2-hour algorithm defined 61.3% of patients as low risk. Sensitivity was 99.1% (94.0%-99.9%) and negative predictive value was 99.9% (99.3%-100%). 24.4% of patients were deemed intermediate risk. When applying the parameters for high risk, 252 (14.3%) were identified, with a specificity of 91.5% (88.7%-93.6%) and a PPV of 42.0% (35.6-48.7%).
CONCLUSIONS: A 2-hour algorithm based on the HighSTEACS strategy using the Siemens Atellica IM hs-cTnI laboratory-based assay enables safe and efficient risk assessment of emergency patients with suspected AMI.
TRIAL REGISTRATION NUMBER: ACTRN12621000053820.
参考来源
- Cullen L, Greenslade JH, Stephensen L, et al. External validation of a rapid algorithm using high-sensitivity troponin assay results for evaluating patients with suspected acute myocardial infarction. Emerg Med J. 2024. PMID: 38316538. doi:10.1136/emermed-2023-213539
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。